Document:

Exhibit 4. 5 

 

SERVICE MANAGEMENT AGREEMENT

 

THIS AGREEMENT is between Can-Fite Biopharma
Ltd., an Israeli company, whose address is 10 Bareket Street, Petach Tikva, Israel (the “Company”) and F.D.
Consulting International and Marketing Ltd., an Israeli company, whose address is City Gate Building, Ben Gurion Street, Herzliya,
Israel. (“Manager”), for services as hereinafter provided is entered as of June 27 2002 (“Effective Date”).

 

		1.	ENGAGEMENT OF SERVICES. 

 

The Company
hereby retains Manager, and Manager hereby agrees to be retained by the Company on the terms and conditions contained herein in
order to provide the Company with such services set forth herein (the “Services”). Services will be rendered to
the best of Manager’s ability, in accordance with the terms of this Agreement. The Services will be performed by Prof. Pnina Fishman,
who will serve as the Company’s Chief Scientific Officer (“Pnina”). Pnina personally agrees to abide to all the
terms and conditions hereto, including without limitation, the obligations of non competition, assignment of inventions and confidentiality.
The Services are the active management of the Company’s research and devlopment activites and such other actions as are associated
with the role of CSO of a biotech company.

 

		l.l.	Manager shall perform such services and duties as are normally incident to the position of Chief
Scientific Officer and are commensurate with Pnina’s background, education and professional standing or as are requested of the
Manager by the Board. In carrying out these functions, Manager shall work at the direction of and subject to the approval of, and
shall report to, the Board of Directors of the Company.

 

		1.2.	Unless otherwise agreed between
                                                                 the parties, Manager shall perform its duties hereunder at the
                                                                 Company’s facilities in Israel only, provided, however,
                                                                 that Manager acknowledges and agrees that the performance of
                                                                 its duties hereunder may require significant international travel.

 

Manager understands and acknowledges
that its services to the Company are essential and that the business and affairs of the Company shall require dedication and all
of Pnina’s business time. It is agreed that Pnina is being engaged in a management position which requires a special degree of
skill and devotion, and therefore Manager undertakes to perform the duties and assignments imposed in the scope of its Services
to the Company with devotion, honesty and fidelity, subject to the Company’s policy as amended from time to time, and to dedicate
to the performance of the said Services all of Pnina’s know-how, qualifications and experience and all the reasonable time, diligence
and attention required for the performance thereof efficiently, with fidelity and in accordance with the requirements of this Agreement,
and to use its best endeavors in order to advance the affairs and business of Company and the realization of its objectives.

 

    	 

    	 

    

 

		1.3.	Manager declares that it is not presently involved, and it undertakes not to become involved in
the future, for so long as Pnina is providing Services hereunder to the Company, in any obligations towards any third party whatsoever
which entail any form of conflict of interest with his Services to the Company.

 

		2.	COMPENSATION.

 

In consideration
of the Services rendered and to be rendered by Manager in accordance with this Agreement, the Company hereby agrees to pay Manager
a monthly amount of Thirteen Thousand Three hundred and Thirty Three US Dollars (US$13,333) (the “Monthly Payment”)
which equals an annual compensation of One Hundred and Sixty Thousand US Dollars (US$160,000)(the “Compensation”).
Such amount shall not include VAT which shall be added to each Monthly Payment.. Unless otherwise agreed between the parties
hereto, the Board of Directors of the Company shall, on an annual basis, each year of the term hereof, review and consider an
increase in the Compensation paid to the Manager for the next 12-month period based on the Manager’s achievments in the
preceding period.

 

Manager
acknowledges and confirms that the Compensation includes remuneration for all its Service for the Company and it shall not be entitled
to any further remuneration or payment whatsoever unless specifically agreed on in this Agreement. Further, Manager acknowledges
that as of the date hereof Company has no debts or liabilities to it whatsoever including without limitation any debts or liabilities
due to it for any prior Services provided to the Company before the date hereof.

 

The Company
shall pay or reimburse Manager for all normal, usual and necessary expenses incurred or paid by Manager in the performance of its
duties hereunder in accordance with such Expense Reimbursement Policy as may from time to time be adopted by the Board.

 

The Board
will set for the Manager certain annual milestones to be achieved during each calendar year. Upon the fulfillment of such annual
milestones, such fullfilment to be determined at the sole discretion of the Board of Directors of the Company, the Manager will
be entitled to receive an annual bonus to be decided by the Board.

 

At the
Board of Directors sole discretion, Manager shall be entitled to participate in a stock option plan approved by the Board. Any
options to be issued as aforesaid, if at all, shall be issued under the Manager’s name, it being clarified that the number of options
to be issued to the Manager, if any, shall be decided by the Board of Directions at its sole discretion taking into account Pnina’s
position and contribution to the Company.

 

    	2

    	 

    

 

In addition,
Manager shall be provided with a Company owned (or leased) automobile (the “Car”) for the use of the Manager (or
Pnina), the type and make as agreed between the Company and the Manager with an engine size not less than 1,600 cc. Any and all
cost related to the purchase or lease of the Car shall be borne by the Company except that any taxes related thereto and traffic
fines shall be paid solely by the Manager or Pnina, as applicable.

 

For the
duration of this Agreement, the Manager shall be entitled to the use of a cellphone owned by the Company. The Company shall pay
any and all expenses related to the use of such cellphone.

 

		3.	INDEPENDENT MANAGER RELATIONSHIP

 

		3.1	Nature of Relationship. Manager’s relationship with the Company will be that of
                                                           an independent Manager and nothing in this Agreement should be construed to create a partnership, joint venture, or
                                                           employer-employee relationship. Both parties hereby expressly state that employee-employer relationship does not exist
                                                           between the Manager (or Pnina) and the Company. Notwithstanding the aforesaid, the Manager (or Pnina) may have fiduciary
                                                           duties towards the Company due to other positions the Manager (or Pnina) may hold, such as directorship, appointment as Chief
                                                           Scientific Officer e.t.c.Pnina shall sign and execute the Indemnification Letter attached hereto as Exhibit 3.1.

 

		3.2	Manager Responsible for Taxes and
                                                           Records. Manager will be solely responsible for all tax returns
                                                           and payments required to be filed with or made to any, state or local
                                                           tax authority with respect to Manager’s performance of services
                                                           and receipt of compensation under this Agreement.

 

		4.	NON-COMPETITION

 

		4.1	The Manager understands and recognizes that its services to the Company are special and unique and agrees that during the term
of this Agreement and for a period of twelve (12) months after the termination of this Agreement it shall not in any manner, directly
or indirectly, on behalf of itself or any person, firm, partnership, joint venture, corporation or other business entity (“Person”),
either for its own account, or as an advisor, partner, joint venturer, executive, agent, consultant, licensor, licensee, salesperson,
officer, director or shareholder or in any other capacity whatever of a Person, enter into or engage in any business which is engaged
in any activities competing directly with products or services offered by the Company. Notwithstanding the aforesaid, after the
termination of this Agreement, Manager (or Pnina) may be active and engage in research activities which may compete directly with
the products or services offered by the Company provided that they are solely for pure academic purposes with no a priori
intention to be commercialized.

 

    	3

    	 

    

 

		4.2	During the period of this Agreement and for a period of
twelve (12) months after the termination of this Agreement, the Manager shall not interfere directly or indirectly, including personally
or in any business in which he is an officer, director or shareholder with or disrupt or attempt to disrupt the Company’s business
relationship with any of its customers, partners, shareholders or suppliers, or solicit any of the employees of the Company.

 

		5.	CONFIDENTIAL INFORMATION

 

		5.1	The
Manager agrees that during the course of its engagement or at any time after expiration or termination thereof, it will not disclose
or make accessible to any Person, any information of the Company which is, by its nature, confidential, including, without limitation,
information concerning products, services and technology, both current and under development, promotion and marketing programs,
lists, trade secrets and other confidential and proprietary business information (collectively, “Confidential Information”)
of the Company, except to the extent required by law. The Manager shall not use any such information, directly or indirectly,
for itself or others except as required in connection with its duties to the Company. The Manager agrees to return all such material
and reproductions thereof (whether or not merged with other works) in its possession to the Company promptly upon request and
in any event immediately upon termination of this Agreement.For
purposes of this Agreement, Confidential Information shall not include information which (i) is in, or enters the public domain
otherwise than by reason of a breach of this Agreement by Manager; or (ii) is proved to have been known to Manager prior to the
commencement of his association with the Company either as a service provider or a director.

 

		5.2	The Manager understands that the Company is engaged in a continuous program of research, development, production and marketing
in connection with its business and that, as an essential part of his service with the Company, it is expected to make new contributions
to and create inventions of value for the Company. Manager agrees to share with the Company all its knowledge and experience.

 

		5.3	From and after the date Manager first became associated with the Company; Manager undertakes
and covenants that it will promptly disclose in confidence to the Company all inventions, improvements, designs, original works
of authorship formulas, concepts, techniques, methods, systems, processes, compositions of matter, computer software programs,
databases, mask works, and trade secrets, all which are related to the Company’s business including current or anticipated research
and development, whether or not patentable, copyrightable or protectable as trade secretes, that are made or conceived or first
reduced to practice or created by it, either alone or jointly with others during the period of its engagement by the Company whether
or not in the course of its service to the Company (“Inventions”).

 

    	4

    	 

    

 

		5.4	The Manager hereby irrevocably assigns to the Company
all right, title and interest it may have or acquire in all Inventions that (a) are or were developed, whole or in part on Company’s
time or with the use of any equipment, supplies, facilities or trade secrets of the Company, (b) result directly from any work
performed by it for the Company, or (c) relate to the Company’s business or current or anticipated research and development (“Company
Inventions”), and agrees that all such Company Inventions shall be the sole property of the Company and its assigns, and the
Company and its assigns shall be the sole owner of all patents, copyrights and other rights in connection therewith.

 

		5.5	Manager
further agrees to assist the Company in every proper way (but at the Company’s expense) to obtain and from time to time enforce
patents, copyrights or other rights on said Company Inventions in any and all countries. Manager will execute any documents that
the Company may reasonably request for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets
and other legal protections. Manager obligation under this Section 5.5 will continue beyond the termination of his Agreement
with the Company, provided that the Company will compensate Manager at a reasonable rate after such termination for time or expenses
actually spent by Manager at the Company’s request on such assistance. The Manager hereby irrevocably appoints the Secretary of
the Company as its attorney-in-fact to execute documents on its behalf for this purpose.

 

		5.6	The Manager hereby irrevocably transfers and assigns and will transfer
                                                           and assign in the future to the Company (a) all worldwide patents,
                                                           patent applications, copyrights, mask works, trade secrets and other
                                                           intellectual property rights in any Company Invention; and (b) any
                                                           and all “Moral Rights” (as defmed below) that he may have
                                                           in or with respect to any Company Invention. Manager also hereby forever
                                                           waives and agrees never to assert any and all Moral Rights he may have
                                                           in or with respect to any Company Invention, even after termination
                                                           of its service for the Company. “Moral Rights” mean
                                                           any rights to any Invention, other than that defined under subsection
                                                           (a) of this Section 5.6.

 

		5.7	Inventions,
                                                                                                                                       if
                                                                                                                                       any,
                                                                                                                                       patented
                                                                                                                                       or
                                                                                                                                       unpatented,
                                                                                                                                       which
                                                                                                                                       Manager
                                                                                                                                       made
                                                                                                                                       prior
                                                                                                                                       to
                                                                                                                                       the
                                                                                                                                       commencement
                                                                                                                                       of
                                                                                                                                       his
                                                                                                                                       engagment
                                                                                                                                       with
                                                                                                                                       the
                                                                                                                                       Company
                                                                                                                                       are
                                                                                                                                       excluded
                                                                                                                                       from
                                                                                                                                       the
                                                                                                                                       scope
                                                                                                                                       of
                                                                                                                                       this
                                                                                                                                       Agreement.
                                                                                                                                       To
                                                                                                                                       preclude
                                                                                                                                       any
                                                                                                                                       possible
                                                                                                                                       uncertainty,
                                                                                                                                       Exhibit
                                                                                                                                       A
                                                                                                                                       (Previous
                                                                                                                                       Inventions)
                                                                                                                                       attached
                                                                                                                                       hereto
                                                                                                                                       is
                                                                                                                                       a
                                                                                                                                       complete
                                                                                                                                       list
                                                                                                                                       of
                                                                                                                                       all
                                                                                                                                       Inventions
                                                                                                                                       that
                                                                                                                                       Manager
                                                                                                                                       have,
                                                                                                                                       alone
                                                                                                                                       or
                                                                                                                                       jointly
                                                                                                                                       with
                                                                                                                                       others,
                                                                                                                                       conceived,
                                                                                                                                       developed
                                                                                                                                       or
                                                                                                                                       reduced
                                                                                                                                       to
                                                                                                                                       practice
                                                                                                                                       or
                                                                                                                                       caused
                                                                                                                                       to
                                                                                                                                       be
                                                                                                                                       conceived,
                                                                                                                                       developed
                                                                                                                                       or
                                                                                                                                       reduced
                                                                                                                                       to
                                                                                                                                       practice
                                                                                                                                       prior
                                                                                                                                       to
                                                                                                                                       the
                                                                                                                                       commencement
                                                                                                                                       of
                                                                                                                                       his
                                                                                                                                       engagment
                                                                                                                                       with
                                                                                                                                       the
                                                                                                                                       Company,
                                                                                                                                       (collectively
                                                                                                                                       referred
                                                                                                                                       to
                                                                                                                                       as
                                                                                                                                       “Prior
                                                                                                                                       Inventions”).
                                                                                                                                       If
                                                                                                                                       no
                                                                                                                                       such
                                                                                                                                       disclosure
                                                                                                                                       is
                                                                                                                                       attached,
                                                                                                                                       Manager
                                                                                                                                       represents
                                                                                                                                       that
                                                                                                                                       there
                                                                                                                                       are
                                                                                                                                       no
                                                                                                                                       Prior
                                                                                                                                       Inventions.

 

    	5

    	 

    

 

		6.	TERM;
TERMINATION

 

The Manager
shall commence providing the Services to the Company on the Effective Date and shall continue unless terminated by either party
(“Termination Without Cause”) provided that the terminating party provided at least three (3) months
advance written notice of such termination to the other party (the “Notice Period”). This Agreement
shall terminate immediately upon the expiry of the Notice Period. Notwithstanding the aforesaid, the Company may terminate this
Agreement immediatly without having to provide the Notice Period in any of the following events: (a) a serious breach of trust
including but not limited to theft, embezzlement, self-dealing; (b) any willful failure to perform competently any of his fundamental
functions or duties hereunder which is not remedied by Manager within a reasonable time of having been requested to do so by the
Company; (c) Manager (or Pnina) is convicted by a competent court of law of a dishonorable criminal offence () or (d) without Company’s prior approval, Pnina ceases to perform the services on behalf of the Manager.

 

In the event of Termination Without
Cause by the Company, the period set out in Section 4.1 and 4.2 above shall be reduced to six (6) months.

 

		7.	GENERAL
PROVISIONS

 

		7.1	Cooperation. The parties will cooperate with each other
                                                           in order to implement this Agreement in accordance with the intent
                                                           of the parties thereof.

 

		7.2	Governing Law. This Agreement will be governed and construed
                                                           in accordance with the laws of the State of Israel.

 

		7.3	Entire Agreement. This agreement sets forth the entire understanding
                                                           and agreement of the parties as the subject matter of this Agreement,.
                                                           It may not be changed orally but only by a written document signed
                                                           by both parties. The obligations set out in Sections 4 and 5 of this
                                                           Agreement shall apply also with regard to the duration where Manager
                                                           (or Pnina) was previously assoicated with the Company.

 

		7.4	Severability: Waiver. If any provision of this Agreement
                                                           is held to be invalid or unenforceable for any reason, the remaining
                                                           provisions will continue in full force without being impaired or invalidated
                                                           in any way. The Company and Manager agree to replace any invalid provision
                                                           with a different provision, which most closely approximates the intent
                                                           and economic effect of the invalid provision. The waiver of any breach
                                                           by either party will not operate or be interpreted as a waiver of any
                                                           other or subsequent breach by such party.

 

    	6

    	 

    

 

		7.5	Successors and Assigns.
                                                                  Neither this Agreement nor any of the rights or obligations
                                                                  of each party hereto arising under this Agreement may be assigned
                                                                  or transferred without prior written consent from the other
                                                                  party hereto.

 

		7.6	Headings. Titles or headings to the sections of this
                                                                Agreement are not part of the terms of this Agreement, but are
                                                                inserted solely for convenience.

 

		7.7	Notices. All notices, requests and other communications
                                                           under this Agreement must be in writing and must be mailed by registered
                                                           or certified, postage prepaid and return receipt requested, or delivered
                                                           by hand to the party to whom such notice is required or permitted to
                                                           be given. If mailed, any such notice will be considered to have been
                                                           given three business days after it was mailed, as evidenced by the
                                                           postmark. If delivered by hand, any such notice will be considered
                                                           to have been given when received by the party to whom notice is given,
                                                           as evidenced by written and dated receipt of the receiving party. The
                                                           mailing address for notice to either party will be the address shown
                                                           on the signature page of this agreement. Either party may change its
                                                           mailing address by notice as provided by this Section 7.7.

 

In
Witness whereof the parties have executed this Agreement on the date above.

 

	Can-Fite Biopharma Ltd.	 	F.D. Consulting International and Marketing Ltd.
	 	 	 
	/s/ Ilan Cohn	 	/s/ Pnina Fishman
	By:	Ilan Cohn	 	By: Prof. Pnina Fishman
	Title:	CEO	 	Title:	 	 

 

I hereby personally agree to abide to all the terms and conditions
hereto.

 

	/s/ Pnina Fishman	 
	Pnina Fishman	 

 

    	7

    	 

    

 

Exhibit A

 

All patents and patent applications relating
to the use of IVIG (Intravenous Gamma Globulin) or fractions thereof in cancer treatment that were assigned to ARP Biomed.

 

    	8Exhibit 4. 6 

 

	Canfite BioPharma	ACP10004

 

 

Master Services Agreement

 

Accellient Partners LLC

A Massachusetts Limited Liability Company

 

1000 Winter Street

Suite 2000

Waltham, Massachusetts 02451

USA

 

    	 	Page 1 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

MASTER SERVICES AGREEMENT

 

Effective 10 May 2010 (the "Effective Date"), Accellient
Partners, LLC, (“ACCELLIENT PARTNERS”) located at 1000 Winter St., Suite 2000, Waltham, MA 02451 and Canfite
BioPharma Ltd. (“CLIENT”) located at 10 Bareket Street, Petach-Tivka, 49170, Israel, seek to enter into an agreement
whereby ACCELLIENT PARTNERS shall provide consulting and project management services to CLIENT.

 

The scope of work and services shall be outlined in one or more
Work Orders (each a “Work Order”). Upon agreement to the terms of such Work Order, ACCELLIENT PARTNERS shall perform
the consulting services for CLIENT described in such Work Order (the “Services”). Each Work Order may but is not required
to be attached hereto, from time to time, collectively, as Exhibits. Each Work Order which shall be subject to the provisions of
this Agreement, is made fully a part hereof. Regardless of whether a Work Order is attached to a copy of this Agreement, it is
understood and agreed that this Agreement shall control the relationship of CLIENT and ACCELLIENT PARTNERS with respect to any
and all Work Orders.

 

Accordingly, ACCELLIENT PARTNERS and CLIENT agree as follows:

 

1. Services. CLIENT hereby retains ACCELLIENT PARTNERS and ACCELLIENT
PARTNERS agrees to undertake and complete the consulting services (“Consulting Services”) as CLIENT may from time to
time request.

 

a) ACCELLIENT PARTNERS’ Personnel. ACCELLIENT PARTNERS
has, and if necessary will engage, employees, subcontractors and/or consultants (“ACCELLIENT PARTNERS’ Personnel”)
with the proper skill, training and experience to provide the Consulting Services. Before providing Consulting Services, all ACCELLIENT
PARTNERS’ Personnel must have agreed in writing to confidentiality obligations at least as stringent as those set forth in
this Agreement. ACCELLIENT PARTNERS agrees to have an agreement in place with all ACCELLIENT PARTNERS’ Personnel that assigns
and otherwise effectively vests in ACCELLIENT PARTNERS all rights to the products of their work.

 

b) Third Party Confidential Information. ACCELLIENT PARTNERS
agrees not to disclose or incorporate confidential information of any other person, firm, corporation, institution or other entity
in connection with any of the Consulting Services.

 

    	 	Page 2 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

c) Subcontracting. ACCELLIENT PARTNERS may subcontract the performance
of certain of its obligations hereunder to qualified third parties, provided that ACCELLIENT PARTNERS notifies CLIENT of the proposed
subcontractor and identifies the specific Consulting Services to be performed by the subcontractor. At the request of CLIENT, ACCELLIENT
PARTNERS agrees to provide CLIENT with a copy of ACCELLIENT PARTNERS’ agreement with any subcontractors rendering Consulting
Services, which copy may be redacted to eliminate any confidential information.

 

2. Payment. In consideration of CLIENT’s acceptance
of this AGREEMENT, CLIENT shall pay ACCELLIENT PARTNERS as specified in the Work Order for Consulting Services provided
by ACCELLIENT PARTNERS.

 

3. Records. All papers, records, data,
documents, and other materials, including copies, electronic and optical media, and computerized records that ACCELLIENT PARTNERS
possesses or creates as a result of performing Consulting Services hereunder (collectively "Records") are the sole and
exclusive property of CLIENT. ACCELLIENT PARTNERS shall use commercially reasonable efforts to maintain all Records in a safe and
secure manner during the term of this Agreement and for one year after expiration or earlier termination of this AGREEMENT (or
such shorter period specified by CLIENT), after which time ACCELLIENT PARTNERS may dispose of all non-original Records. Original
GMP, GLP, GCP study Records and original regulatory submission documents will be returned to the CLIENT or sent to permanent secure
off site storage at CLIENT’S expense. ACCELLIENT PARTNERS shall make any and all Records available for inspection or duplication
by CLIENT's authorized representatives, with notice, and shall deliver the same at any time to a location specified by written
instruction of CLIENT to ACCELLIENT PARTNERS.

 

4. Debarment. ACCELLIENT PARTNERS
warrants and represents that neither ACCELLIENT PARTNERS nor, to its knowledge, any ACCELLIENT
PARTNERS Personnel has ever been, nor is currently, debarred under the Federal Food, Drug and Cosmetic Act. ACCELLIENT PARTNERS
further represents and warrants that it has not and shall not knowingly use in any capacity the services of any individual, corporation,
partnership, or association that has been debarred under the Federal Food, Drug and Cosmetic Act. In the event ACCELLIENT PARTNERS
or any ACCELLIENT PARTNERS personnel becomes debarred or receives a notice of an action or threat of an action with respect to
debarment, ACCELLIENT PARTNERS shall immediately notify CLIENT, and CLIENT shall have the right to
terminate this AGREEMENT immediately upon written notice to ACCELLIENT PARTNERS without any further obligation or liability hereunder.

 

    	 	Page 3 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

5. Inventions.
All inventions, (whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas, techniques
and information in possession of ACCELLIENT PARTNERS on or before the Effective Date of this Agreement (collectively "ACCELLIENT
PARTNERS INVENTIONS") shall be owned exclusively by ACCELLIENT PARTNERS. Any improvements to or developments of ACCELLIENT
PARTNERS INVENTIONS made after the effective date of this Agreement shall belong exclusively to ACCELLIENT PARTNERS. Improvements
to ACCELLIENT PARTNERS INVENTIONS made under the terms of this Agreement shall be made available to CLIENT by way of a nonexclusive
worldwide royalty-free license which ACCELLIENT PARTNERS hereby grants to CLIENT. CLIENT shall own all right, title and interest
(including patent rights, copyrights, trade secret rights, mask work rights, trademark rights, sui generis database rights
and all other intellectual and industrial property rights of any sort throughout the world) relating to any and all deliverables,
reports, inventions (whether or not patentable), works of authorship, mask works, designations, designs, know-how, ideas, techniques,
improvements and information, other than ACCELLIENT PARTNERS INVENTIONS, made or conceived or reduced to practice, in whole or
in part, by ACCELLIENT PARTNERS in connection with the Consulting
Services or any Proprietary Information (as defined below) (collectively, “CLIENT Inventions”) and ACCELLIENT PARTNERS
will promptly disclose and provide all CLIENT Inventions to CLIENT. ACCELLIENT PARTNERS hereby makes all assignments necessary
to accomplish said assignment and will take such additional steps as reasonably necessary, at CLIENT's direction and expense (including
ACCELLIENT PARTNERS' costs for ACCELLIENT PARTNERS' employees and consultants' time), to prepare necessary documents in connection
with the assignment.

 

6. Confidentiality.

 

a) ACCELLIENT PARTNERS agrees that all Inventions and all
other business, technical and financial information (including, without limitation, the identity of and information relating to
customers or employees of CLIENT) ACCELLIENT PARTNERS learns, creates or obtains in connection with Services or that are received
by or for CLIENT in connection with the Consulting Services, constitute “Client Proprietary Information” except as
required or necessary by law or regulation. ACCELLIENT PARTNERS, however, shall not be obligated under this paragraph 6 with respect
to information ACCELLIENT PARTNERS can document: (i) is or becomes readily publicly available without restriction through no fault
of ACCELLIENT PARTNERS; (ii) was known to ACCELLIENT PARTNERS prior to the date of this Agreement
and is not subject to another confidentiality obligation to Client; or (iii) was developed or discovered by ACCELLIENT PARTNERS
without reference to CLIENT Proprietary Information.

 

b) Upon termination and as otherwise
requested by CLIENT, ACCELLIENT PARTNERS will promptly return to CLIENT all items and copies containing or embodying CLIENT Proprietary
Information, except that ACCELLIENT PARTNERS may keep copies of its own compensation records and CLIENT Proprietary information
as may reasonably be required for ACCELLIENT PARTNERS to comply with law or regulation, and this Agreement.

 

    	 	Page 4 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

7. Warranties and Representations. ACCELLIENT PARTNERS warrants
and represents the following:

 

a) The Consulting Services will be performed
in a professional and workmanlike manner consistent with the highest prevailing applicable industry standards.

 

b) Neither the Consulting Services nor any part of this Agreement
is or will be inconsistent with any obligation ACCELLIENT PARTNERS may have to any other party.

 

c) THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE
THE SOLE AND EXCLUSIVE WARRANTIES MADE BY ACCELLIENT PARTNERS TO CLIENT. THERE ARE NO OTHER WARRANTIES,
REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, REGARDING THE PRODUCTS, MATERIALS, OR SERVICES
TO BE SUPPLIED UNDER THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT,
OR FITNESS FOR A PARTICULAR PURPOSE.

 

8. Termination. The term of this AGREEMENT shall begin on the
Effective Date and shall remain in force until the conclusion of the project or for 2 (two) years whichever comes first (the “Initial
Term”), and this AGREEMENT will automatically renew under the same terms on a month-to-month basis until the renewal is terminated
by either party upon delivery to the other party of thirty (30) days written notice.

 

a) Termination by CLIENT: CLIENT may immediately terminate
this Agreement at any time upon written notice to ACCELLIENT PARTNERS in the event of a breach of this Agreement by ACCELLIENT
PARTNERS which cannot be cured (e.g., breach of the confidentiality obligations). Further, following the expiration of the
Initial Term, CLIENT may terminate this AGREEMENT without cause by giving thirty (30) days prior written notice to ACCELLIENT PARTNERS.

 

b) Termination by ACCELLIENT PARTNERS: ACCELLIENT
PARTNERS may terminate this Agreement upon thirty (30) days prior written notice to CLIENT if CLIENT breaches this Agreement
and such breach is not cured within the notice period.

 

    	 	Page 5 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

c) Effect of Expiration or Termination. Upon expiration
or termination of this Agreement, neither ACCELLIENT PARTNERS nor CLIENT will have any further obligations under this Agreement,
except that (a) ACCELLIENT PARTNERS will terminate all Consulting Services in progress in an orderly manner as soon as practical
and in accordance with a schedule agreed to by CLIENT, unless CLIENT specifies in the notice of termination that Consulting Services
in progress should be completed, (b) ACCELLIENT PARTNERS will deliver to CLIENT any Records in its
possession or control and all Inventions developed through expiration or termination, (c) CLIENT will pay ACCELLIENT PARTNERS any
monies due and owing CLIENT, up to the time of termination or expiration, for Consulting Services actually performed and all authorized
expenses actually incurred, (d) ACCELLIENT PARTNERS will promptly refund to CLIENT any monies paid by CLIENT in advance for Consulting
Services not rendered, (e) ACCELLIENT PARTNERS will immediately return to CLIENT all Proprietary Information and copies
thereof provided to ACCELLIENT PARTNERS under this Agreement except for one (1) copy which ACCELLIENT PARTNERS may retain solely
to monitor ACCELLIENT PARTNERS’ surviving obligations of confidentiality, and (f) the terms, conditions and obligations under
Sections 2, 3, 4, 5, 7(c) and 10 through 15 will survive expiration or termination for any reason.

 

9. Relationship of the Parties. Notwithstanding any provision
hereof, for all purposes of this Agreement each party shall be and act as an independent contractor and not as partner, joint venturer,
or agent of the other and shall not bind nor attempt to bind the other to any contract. ACCELLIENT PARTNERS is an independent contractor
and is solely responsible for all taxes, withholdings, and other statutory or contractual obligations of any sort.

 

10.
Indemnification:

a) ACCELLIENT PARTNERS will indemnify and hold harmless CLIENT
and its Affiliates and their officers, directors, employees and agents from and against any liability, loss, damage, action, claim
or expense (including reasonable attorney’s fees) (collectively, “Losses”) actually incurred and arising from
any third party claim relating to (a) a failure by ACCELLIENT PARTNERS to perform the Services materially in accordance with the
terms of this Agreement or any such applicable law(s) or regulation(s); or (b) ACCELLIENT PARTNERS’ gross negligence or willful
misconduct; in each case save for any Losses for which CLIENT is obligated to indemnify ACCELLIENT PARTNERS hereunder.

 

b) CLIENT will indemnify and
hold harmless ACCELLIENT PARTNERS and its Affiliates and their officers, directors, employees and agents from and against any Losses
arising from any third party claim relating to (a) CLIENT's research, development, manufacturing, commercialization, exploitation,
use or sale of a product; (b) the use or sale of or exposure to a product or any material provided to ACCELLIENT PARTNERS by CLIENT;
(c) ACCELLIENT PARTNERS' or CLIENT's use of any of CLIENT's Intellectual Property Rights or any claims of infringement based on
any materials or requests for Services provided by CLIENT to ACCELLIENT PARTNERS under this Agreement, or (d) ACCELLIENT
PARTNERS' performance of the Services in compliance with this Agreement, in each case save for any Losses for which ACCELLIENT
PARTNERS is obligated to indemnify CLIENT hereunder.

 

    	 	Page 6 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

c) The indemnified party will notify the indemnifying party
forthwith upon becoming aware of the claim, and take all action reasonably requested by the indemnifying party to avoid, compromise
or defend the claim, and any proceedings in respect of the claim, subject to the indemnified party being indemnified by the indemnifying
party as provided in this Section, and secured to its reasonable satisfaction against all costs and expenses which may be incurred
by doing so. The indemnified party’s failure to so notify the indemnifying party or take all action reasonably requested
by the indemnifying party will not relieve the indemnifying party of its obligations under this Section unless the indemnifying
party is materially prejudiced thereby.

 

11. Insurance. ACCELLIENT PARTNERS carries, with financially
sound and reputable insurers, worker’s compensation insurance with benefits determined by statute.

 

12. Limitation on Liability.
NOTWITHSTANDING ANY OTHER PROVISION IN THIS AGREEMENT, ACCELLIENT PARTNERS’S LIABILITY TO CLIENT UNDER THIS AGREEMENT FOR
ANY BREACH OF THIS AGREEMENT WILL NOT EXCEED AN AMOUNT EQUAL TO THE TOTAL AMOUNT ACTUALLY PAID BY CLIENT TO ACCELLIENT PARTNERS.
IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY OTHER PERSON FOR ANY SPECIAL,
CONSEQUENTIAL, EXEMPLARY, OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), WHETHER
OR NOT FORESEEABLE, ARISING FROM OR RELATING TO THIS AGREEMENT OR THE SUBJECT MATTER THEREOF.

 

13. Assignment. Except as provided in Section 1(c), this
Agreement may not be assigned by ACCELLIENT PARTNERS without the prior written consent of CLIENT. No assignment will relieve either
party of the performance of any accrued obligation that such party may then have under this Agreement.

 

14. Use of Name. Neither party may use the other party’s
name in any form of advertising, promotion or publicity, including press releases, without the prior written consent of
the other party. ACCELLIENT PARTNERS, however, consents to the use by CLIENT of ACCELLIENT PARTNERS’ name and likeness in
written materials and oral presentations to current or prospective customers, partners, investors or others, provided that the
materials or presentations accurately describe the nature of ACCELLIENT PARTNERS’ relationship with or services to CLIENT.
This section does not restrict a party’s ability to use the other party’s name in filings with the Securities and Exchange
Commission, FDA, or other governmental agencies, when required to do so.

 

15.
Notice. All notices under this Agreement shall be in writing, and shall be deemed given when personally delivered, or three (3)
days after being sent by prepaid certified or registered U.S. mail to the address of the party to be noticed as
set forth herein or such other address as such party last provided to the other by written notice.

 

    	 	Page 7 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma Ltd.	AP Contract Number

 

16. Irreparable
Injury: Any breach of Section 6 that may cause irreparable harm to CLIENT for which damages would not be an adequate remedy, and,
therefore, CLIENT will be entitled to seek injunctive relief with respect thereto in addition to any other remedies.

 

17. Miscellaneous: The failure of either
party to enforce its rights under this Agreement at any time for any period shall not be construed as a waiver of such rights.
No changes or modifications or waivers to this Agreement will be effective unless in writing and signed by both parties. In the
event that any provision of this Agreement shall be determined to be illegal or unenforceable, that provision will be limited or
eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable.
This Agreement shall be governed by and construed in accordance with the laws of Massachusetts without regard to the conflicts
of laws provisions thereof. Headings herein are for convenience of reference only and shall in no way affect interpretation of
the Agreement.

 

The duly authorized representatives of
ACCELLIENT PARTNERS and CLIENT have executed this Consulting Agreement on the date first written above.

 

	ACCELLIENT PARTNERS LLC	 	CANFITE BIOPHARMA LTD
	 	 	 
	By: 	/s/ William Kerns	 	By: 	/s/ Pnina Fishman
	Name: William Kerns	 	Name: Pnina Fishman
	Title: CEO	 	Title: CEO
	Tel: 978.456.9975	 	Tel: +972-3-9241114
	Email: bill.kerns@accellient.com	 	Email: pnina@canfite.co.il

 

    	23 May 2010	Page 8 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

Exhibit 1

 

WORK ORDER #1

 

Management of Drug Development Programs

 

Effective Date of Work Order: 10 May
2010

 

This
Work Order (“Work Order”) is between ACCELLIENT PARTNERS Inc. (“ACCELLIENT PARTNERS”) located at
1000 Winter St., Suite 2000, Waltham, MA 02451 and Canfite BioPharma
Ltd. (“CLIENT”) located at 10 Bareket Street, Petach-Tivka, 49170, Israel and relates to the Consulting Services
Agreement dated 10 May 2010 (the “CSA”), which is incorporated by reference herein. Pursuant to the CSA, ACCELLIENT
PARTNERS has agreed to perform certain services in accordance with written work orders, such as this one, entered into from time-to-time.

 

SCOPE OF WORK

ACCELLIENT PARTNERS shall provide pharmaceutical and/or device
consulting and project management services to CLIENT in the areas of:

 

Due diligence, investor support, discovery candidate selection,
drug substance and drug product manufacturing, analytical chemistry, formulation development, pharmacology, metabolism, bioanalytical
method development, pharmacokinetics, toxicology, regulatory submissions and/or clinical development (the “Field”)
in pursuit of therapeutic products and/or devices as well as providing services outside of the Field with mutual written agreement
of the parties.

 

Specifically this project covers full development support for
Canfite BioPharma.

 

FEES

In consideration of CLIENT’s acceptance of this
AGREEMENT, CLIENT shall pay ACCELLIENT PARTNERS at the rates specified below for Consulting Services provided by ACCELLIENT
PARTNERS.

 

Table 1. ACCELLIENT PARTNERS’ RATES

 

	 	 	Consulting	 	 	 	 
	Consultant	 	Rate (/hr)	 	 	Travel Rate (/hr)	 
	CEO	 	$	350	 	 	$	175	 
	COO	 	$	250	 	 	$	125	 
	Executive VP	 	$	300	 	 	$	150	 
	Principal (eg. PhD)	 	$	 250-350	 	 	$	137-175	 
	Associate (eg. eCTD/Regulatory Docs/PM)	 	$	150-200	 	 	$	75-100	 
	Clinician (eg., MD)	 	$	400-450	 	 	$	200-225	 

 

    	 	Page 9 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma	ACP10004

 

FIXED COST ACTIVITIES

APTUIT
CONSULTING will invoice client $1200.00 monthly for US office support, (mail,
phone, general administration), US agent fees, Sharepoint filing and document maintenance and retention.

 

Additional consulting services requested outside of those above
may also be provided at the rates outlined in Table 1.

 

ACCELLIENT
PARTNERS shall bill CLIENT monthly for all Consulting Services and each invoice shall provide a detailed accounting by project
and tasks and the total hours spent working on each task. The invoice shall include all office meetings, conferences, phone discussions,
email correspondence, research, and report preparation. Travel time between the hours of 1800 and 0800 will be billed at 50% of
the regular consulting rate as specified in Table 1. Work performed outside ACCELLIENT PARTNERS’ offices will be billed in
4 hour increments for site visits local to the consultant; additional time be billed in one hour increments; work performed at
sites that require air/rail travel will be billed minimally at 8 hours per day with additional hours in 1 hour increments; work
performed in ACCELLIENT PARTNERS’ offices will be billed
in 15 minute increments. ACCELLIENT PARTNERS’ fee schedule
is subject to change with sixty (60) day written notification. Changes in rates will be deemed accepted by the CLIENT thirty (30)
days from the notice of such change.

 

In addition to its other duties of payment under this Agreement,
CLIENT agrees to pay all fees incurred by ACCELLIENT PARTNERS including pass-through expenses, unless CLIENT provides written notice
to ACCELLIENT PARTNERS to cease providing services. Upon receipt of such written notice, ACCELLIENT PARTNERS shall cease work for
the CLIENT and invoice client for fees and pass through expenses incurred through the receipt of notice.

 

CLIENT
shall pre-pay or reimburse ACCELLIENT PARTNERS for all out-of-pocket expenses incurred by ACCELLIENT PARTNERS in the performance
of the Consulting Services. Such expenses include, but are not limited to, express mail delivery, travel, meals, taxis and lodging.
Telephone calls are not reimbursable. All airline travel shall be via commercial airline at full refundable coach fare for travel
less than 5 hours or full business (international) or first (North
America) class fare for travel greater than 5 hours. Expenses will be itemized on each invoice.

 

    	 	Page 10 of 11	CONFIDENTIAL

    	 

    

 

	Canfite BioPharma Ltd.	AP Contract Number

 

INVOICES

Invoices should be sent to:

 

	Client Name:	Canfite BioPharma, Ltd.
	Contact Name:	Motti Farbstein
	Address:	10 Bareket Street, Petach-Tivka, 49170,  Israel
	Email Address:	Motti@canfite.co.il
	Telephone Number:	+972-3-9241114

 

Each invoice is payable upon presentation, net 30 days, unless
disputed in writing. Undisputed amounts not paid within 30 days are subject to interest charges at a rate of 1.5% per month. Such
interest will be accrued and added to subsequent billings. In the event that legal proceedings are required to collect fees and
expenses owed, CLIENT shall pay all reasonable attorneys'fees and other costs of collection.

 

PAYMENTS

All payments must be made in US dollars drawn on a US Bank.
It is preferred that CLIENTS remit payment by wire transfer, especially for international payments. Invoicing directions are stated
on the invoice.

 

The duly authorized representatives of ACCELLIENT PARTNERS and
CLIENT have executed this Work Order on the date first written above.

 

	ACCELLIENT PARTNERS LLC	 	CANFITE BIOPHARMA LTD
	 	 	 
	By: 	/s/ William Kerns	 	By: 	/s/ Pnina Fishman
	Name: William Kerns	 	Name: Pnina Fishman
	Title: CEO	 	Title: CEO
	Tel: 978.456.9975	 	Tel: +972-3-9241114
	Email: bill.kerns@accellient.com	 	Email: pnina@canfite.co.il

 

    	23 May 2010	Page 11 of 11	CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]